THERAVANCE BIOPHARMA INC (TBPH) Stock Income Statement
NASDAQ:TBPH - Nasdaq - KYG8807B1068 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 65.27M | 64.38M | 57.42M | 51.30M | 55.30M | |||
| Cost Of Goods | N/A | N/A | N/A | N/A | N/A | |||
| Gross Profit | N/A | N/A | N/A | N/A | N/A | |||
| Operating Expenses | 110.93M | 106.82M | 110.72M | 130.40M | 293.00M | |||
| Research and Development | 40.13M | 37.64M | 40.62M | 63.40M | 192.30M | |||
| Selling, General, and Administrative Expenses | 70.80M | 69.17M | 70.09M | 67.10M | 100.70M | |||
| Operating Income | -45.66M | -42.44M | -53.29M | -79.10M | -237.70M | |||
| Interest Income/Expense | 1.83M | 2.33M | 6.77M | 2.20M | -7.40M | |||
| Other Income/Expense | N/A | N/A | N/A | 0.00 | 0.00 | |||
| Non Recurring Items | N/A | -4.51M | -2.74M | -15.90M | -20.10M | |||
| Income Before Taxes | -48.35M | -44.61M | -49.27M | -92.80M | -265.20M | |||
| Income Tax | 9.98M | 11.80M | 5.92M | 0.00 | -200.00K | |||
| Net Income | -58.33M | -56.42M | -55.19M | 872.10M | -199.40M | |||
| EBITDA | -39.69M | -36.31M | -47.14M | -75.38M | -231.79M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.19 | -1.16 | -1.00 | 11.84 | -2.86 | |||
| Non GAAP EPS | -1.12 | -1.09 | -0.97 | -0.67 | -2.95 | |||
| Statistics | ||||||||
| Gross Profit Margin | N/A | N/A | N/A | N/A | N/A | |||
| Profit Margin | -89.38% | -87.63% | -96.11% | 1700.00% | -360.58% | |||
| Operating Profit Margin | -69.96% | -65.91% | -92.80% | -154.19% | -429.84% | |||
All data in USD